On June 25, 2024, Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced significant progress in its Phase 2 clinical trial for stenoparib, a treatment for advanced recurrent ovarian cancer. The trial has shown that multiple patients have been on treatment for over 30 weeks, demonstrating the drug's extended clinical benefit. This follows an earlier announcement in May 2024, where stenoparib was reported to have significant tumor shrinkage and long-term disease stability in heavily pre-treated patients. The company has decided to halt patient enrollment to focus on a follow-on trial aimed at accelerating stenoparib's path to regulatory approval. The trial's Principal Investigator, Kathleen N. Moore, MD, highlighted the need for continued development of next-generation PARP inhibitors like stenoparib...Show More

On June 25, 2024, Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced significant progress in its Phase 2 clinical trial for stenoparib, a treatment for advanced recurrent ovarian cancer. The trial has shown that multiple patients have been on treatment for over 30 weeks, demonstrating the drug's extended clinical benefit. This follows an earlier announcement in May 2024, where stenoparib was reported to have significant tumor shrinkage and long-term disease stability in heavily pre-treated patients. The company has decided to halt patient enrollment to focus on a follow-on trial aimed at accelerating stenoparib's path to regulatory approval. The trial's Principal Investigator, Kathleen N. Moore, MD, highlighted the need for continued development of next-generation PARP inhibitors like stenoparib. CEO Thomas Jensen emphasized the drug's favorable safety profile and its potential as a next-generation treatment option. The company plans to present detailed trial data at a high-level scientific conference, adhering to the common rules of such events. The PARP inhibitor market, which is expected to reach $22 billion by 2028, has seen significant interest in drugs with improved tolerability and safety profiles. Stenoparib, which also inhibits Tankyrase 1 and 2, is considered a differentiated therapeutic product due to its dual inhibitory activities and safety profile. Allarity Therapeutics uses its proprietary DRP® companion diagnostic to select patients likely to benefit from stenoparib, which has shown promise in increasing therapeutic benefit rates.